• Phonetics and Speech Sciences
• /
• v.4 no.3
• /
• pp.179-186
• /
• 2012

The aims of this study are to consider auditory physiological characteristics and to confirm audiological evaluation and interpretation in regards to cases of sensorineural hearing loss that observe an abnormal AB gap. Vestibulosaccular hearing occurs when there is an abnormally large air-bone gap (AB gap) in sensorineural hearing loss, also known as pure cochlear conductive hearing loss. Generally, an AB gap is caused by damage to the external and/or middle ear. In conductive hearing loss, loss of air condition hearing occurs due to a loss of resonance in the outer ear and/or impedance mismatching in the middle ear. Most of these types of hearing loss can be treated medically and surgically. However, there is no medical treatment for an AB gap in sensorineural hearing loss and hearing loss can worsen gradually or suddenly. In addition, many studies have reported that head trauma makes hearing loss even more serious. Therefore, in order to differentiate between conductive hearing losses, it is important to check whether or not there is an enlarged vestibular aqueduct by means of temporal bone computerized tomography and/or magnetic resonance imaging.

• Proceedings of the KOSOMBE Conference
• /
• v.1997 no.05
• /
• pp.203-206
• /
• 1997

본 연구는 G7 의료공학기술개발사업의 1차년도 연구결과이다. 본 연구의 최종목표는 청각계통중 내이의 손상에 의한 감각성 난청환자에게 소리를 인식할 수 있게 하는 한국형 인공와우의 개발, 전 음성 난청환자의 음성인식 효율을 높일 수 있는 한국형 인공이소골의 개발 그리고 인공와우 시술환자에게 적합한 재활용 프로그램을 개발하는데 있다. 이를 위하여 지난 1차년도에는 코클리어의 전기생리학적 현상을 규명하고, 이식전극시스템과 그 주변장치를 설계, 평가하였다. 그리고 한국인의 성인사체의 16귀를 측정하여 한국인 체형에 적합한 인공이소골의 설계기준을 확립하였다. 또한, 인공와우 시술 후 청력회복에 필요한 한국형 재활프로그램의 개발을 위하여 인공와우의 coding strategy에 따른 언어분별력 조사, 유소아의 어음특성분석등을 행하였다. 이 연구결과를 토대로 차기년도에는 상용화에 근접한 프로토타잎의 제품개발과 임상실험이 진행되리라 생각된다.

• Proceedings of the KOR-BRONCHOESO Conference
• /
• 1982.05a
• /
• pp.17.1-17
• /
• 1982

In 1965, Rosenberg reported that platinum compounds not only inhibit growth and cell division of E. coli but also has anti-tumor activity. Since then, through animal and clinical experiments by Welsch(1971), Speer(1972), Rossof(1972), Hill(1974), and Wittes(1975), it was proved that Cis-platinum has excellent supressive effects on malignant tumor, especially on head and neck cancer. Accordingly, Cis-platinum is now widely used, sometimes without any other durg, or sometimes with Bleomycin and Methotrexate etc. Inspite of the strong anticancer effect, the use of Cis-platinum is quite often discouraged because of the reports that Cis-platinum causes auditory impairment at high frequencies above the speech range due to inner ear damage and irreversible change in the renal tubules. Since Kohonen et al(1965), Standnicki et al(1974) reported that Cisplatinum has toxic effects at the basal turn of the cochlea using guinea pig, many studies on ototoxicity after infusion of Cis-platinum have been carried out using animals. But the studies on ototoxicity in human beings can hardly be found except in reports by Piel et al(1974) and Hong et al (1979). So the authors did a study which tried to clarify the ototoxic effect by comparing the hearing level after infusion of Cis-plastinum with the hearing level before infusion of Cis-plastinum in 30 patients who was treated with Cis-platinum and admitted to the dept. of otolaryngology of Yonsei University Hospital during 2 years and a half from July. 1979 to March. 1982 and the following results were obtained. 1) The results of auditory evaluation, using the pure tone average, hearing loss of 4kHz and 8kHz, Speech Reception Threshold, PB score, SISI showed that the difference of dosage does not change the hearing level after infusion of Cis-platinum and before infusion of Cis-platinum. 2) Cis-platinum had no effect on the hearing level of patients with conductive hearing loss, or with sensorineural hearing loss, as well as with normal hearing level. 3) The infusion of Cis-platinum did not cause any change in creatinine clearance, creatinine, uric acid, but only one case showed that Cis-platinum caused severe nephrotoxicity. 4) The infusion of Cis-plastinum did not cause any change in hemoglobin, leukocyte count, platelet count and there was no correlation with the amount of infusion. 5) To see the side effect of hydration practiced with the infusion of Cis-platinum, the electrolytes, particularly the K level in the serum was measured. But the results did not show any change. 6) Judging from the results of this study mentioned above, ototoxicity caused by infusion of Cis-platinum can be prevented by sufficient hydration. Also the results might say that the appropriate method of infusion of Cis-platinum might be effective in the patients with head and neck cancer who had sensorineural hearing loss for whom the infusion of Cis-platinum has been absolutely cotraindicated.